Annovis Bio Inc. (NYSE: ANVS) has priced an underwritten public offering of 7,895,000 shares of common stock along with accompanying warrants to purchase up to 7,105,500 additional shares, at a combined offering price of $1.90 per share and warrant. The company expects gross proceeds of approximately $15 million before deducting underwriting discounts and offering expenses. The offering is expected to close on or about March 18, 2025, subject to customary closing conditions.
The net proceeds from the offering are intended to support the continued clinical development of buntanetap, Annovis’ lead drug candidate for Alzheimer’s disease (AD) and Parkinson’s disease (PD). Buntanetap is an investigational once-daily oral therapy that targets the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients. Additionally, proceeds will be used for working capital and general corporate purposes.
Annovis Bio is a Phase 3 clinical-stage biotechnology company headquartered in Malvern, Pennsylvania. The company focuses on developing treatments for neurodegenerative diseases such as AD and PD. The pricing of this offering marks a crucial step in securing the necessary capital to advance buntanetap through late-stage clinical trials. According to the company, the funds will enable continued research and development activities, including ongoing and planned studies.
For more details on the offering, the full press release is available at https://ibn.fm/KRpCW. Investors can also find the latest news and updates on Annovis Bio at the company’s newsroom: https://ibn.fm/ANVS.
This capital raise underscores Annovis Bio’s commitment to addressing the unmet medical needs in Alzheimer’s and Parkinson’s diseases. With an aging global population, the demand for effective treatments continues to rise, and buntanetap’s novel mechanism offers potential as a disease-modifying therapy. The successful completion of this offering provides the financial runway needed to generate pivotal clinical data that could support regulatory filings.
Annovis Bio’s approach to targeting multiple neurotoxic proteins simultaneously sets it apart from other therapies that focus on single pathways. The company’s Phase 3 trials are designed to evaluate buntanetap’s efficacy in improving cognitive and motor function, potentially slowing or reversing disease progression. The proceeds from this offering are critical to maintaining the momentum of these studies.
For more information about Annovis Bio and its pipeline, visit www.annovisbio.com. The company also maintains a presence on LinkedIn, YouTube, and X for updates.